Organic Synthesis Pharmaceutical Industries Co., Ltd.

Founded Organic Synthesis Industries Co., Ltd. for the production of tobacco fragrances

Since our founding in 1947, we have long been engaged in research and development in the field of organic chemistry.

Acquisition of Maeno factory (later renamed Maeno plant)

Commenced production of "glycine", "isoniazid", and "nicotinamide"

The manufacturing technology for amino acids such as glycine, which our company first began manufacturing and selling in Japan in 1952, is a representative technology of our company.

Commenced production of "β-alanine" and "pink mint"

Commenced production of "2-vinylpyridine"

Commenced production using a new method for "glycine" and "β-alanine"

Renamed to Organic Synthesis Pharmaceutical Industries Co., Ltd. and moved headquarters to Takaracho, Chuo-ku. Listed on the Second Section of the Tokyo Stock Exchange

Renamed to "Organic Synthesis Pharmaceutical Industry Co., Ltd."

Relocated headquarters to Takaracho, Chuo-ku.

Listed on the Second Section market of the Tokyo Stock Exchange.

Commenced production of "triamcinolone"

Commenced operation of Jōban plant. Commenced production of "peace fragrance"

Jōbō plant commenced operations

Started production of "Peace fragrance."

Commenced production of "protamine sulfate" and "MF fragrance"

Production of "Leucine acid" and "Highlight fragrance" begins

Production of "Niacinamide" begins with a new method. Production of "3-cyanopyridine" begins

Started production using a new method for "Nicotinamide."

Started production of "3-Cyanopyridine."

Production of "8-hydroxykynoline" and "Seventh Star fragrance" begins

Production of "Amino acid sugar (Eukix)" begins

Production of "Cherry fragrance" begins

Production of "Glycine" begins with new equipment

Production of "Niacinamide" begins with new equipment. Tokyo Research Institute completed

Start of production with new nicotinamide equipment

Tokyo Research Institute completed

Production of "Imidazolidin-2-one" begins

Production of "Pesticide intermediate" and "Picolinic acid" begins

Production of "C-P extract" begins

Production of "3-aminopyridine" begins

Production of "DNA" begins. Active sludge treatment plant completed at Iwaki Plant

Production of "DNA" commenced

Jōbō plant activated sludge treatment facility completed

New test plant equipment installed at Tokyo Research Institute

New tobacco fragrance and related material manufacturing equipment installed at Iwaki Plant

New multipurpose manufacturing equipment installed at Iwaki Plant

Production of "Silicon-related products" begins

Production of "4-aminopyridine" and "Isonicotinamide" begins

New pharmaceutical intermediate purification plant installed at Iwaki Plant. Capital increased to 2.55 billion yen

New pharmaceutical intermediate purification plant at Jōbō factory

Capital increase to 2.55 billion yen

Headquarters moved to Hirakawa-cho, Chiyoda-ku. New silicon and Grignard reagent manufacturing equipment installed at Iwaki Plant

Relocation of headquarters to Hirakawa-cho, Chiyoda-ku

New silicon and Grignard reagent manufacturing plant at Jōbō factory

New multipurpose small-scale production equipment installed at Iwaki Plant

Relocated headquarters to current location. Established an experimental building (Technology Development Center) at the Iowan factory. Set up new DNA manufacturing equipment.

Relocation of headquarters to current location

New experimental building (Technology Development Center) at Jōbō factory

New DNA manufacturing plant at Jōbō factory

Moved 2-vinylpyridine manufacturing equipment from the Tokyo Research Institute to the Iowan factory. Obtained ISO 9002 certification at the Iowan factory. Established new dedicated manufacturing equipment for silicon and Grignard-related products.

Relocation of 2‑vinylpyridine manufacturing plant from Tokyo Research Institute to Jōbō factory

ISO 9002 certification obtained at Jōbō factory

New dedicated manufacturing plant for silicon and Grignard-related products at Jōbō factory

Capital increase to 3.471 billion yen

Start of production of trifluorothymine

Started production of "Trifluoromethylimidazole." Increased capital to 3.471 billion yen.

Obtained ISO 9001 certification at headquarters, Osaka sales office, Iowan factory, and Tokyo Research Institute. Established new clinical trial drug research equipment at the Iowan factory.

ISO 9001 certification obtained at headquarters, Osaka sales office, Jōbō factory, and Tokyo Research Institute

New clinical trial drug research facility at Jōbō factory

ISO 14001 certification obtained

Started production of "Yuki" furostanol. Subsidiary "Yuki Engineering Co., Ltd." renamed to "Yuki Techno Service Co., Ltd." Established new pharmaceutical manufacturing equipment at the Iowan factory.

Start of production of Fudostein "Yuki"

Subsidiary "Yuki Engineering Co., Ltd." renamed to "Yuki Techno Service Co., Ltd."

New pharmaceutical manufacturing plant at Jōbō factory

Selected as a listed stock. Established new quality control building at the Iowan factory.

Selected for listed securities

New quality control building at Jōbō factory

Designated as a First Section stock on the Tokyo Stock Exchange. Started operation of integrated core business system.

Listed as a First Section stock on the Tokyo Stock Exchange

Start of operation of the integrated core business system

Established a European office as an overseas base.

Established new liquefied natural gas fuel conversion equipment.

Started production of "Active Pharmaceutical Ingredients for Generic Drugs."

Implemented a co-generation system.

New pharmaceutical intermediate manufacturing facility established

FSSC 22000 certification obtained

Changed classification to the Standard market on the Tokyo Stock Exchange.

Established new glycine production equipment.